Summary
LUX-Lung 5 is the first prospective randomized, phase 3 trial to demonstrate superior progression-free survival by continuing afatinib plus paclitaxel as fourth-line treatment vs single-agent chemotherapy in patients with non–small cell lung cancer who had disease progression on chemotherapy with the combination of erlotinib plus gefitinib and with afatinib monotherapy with a manageable safety profile.
- metastatic non–small cell lung cancer
- LUX-Lung 5
- afatinib
- erlotinib
- gefitinib
- paclitaxel
- fourth-line treatment
- progression-free survival
- overall survival
- disease control rate
- overall response
- oncology clinical trials
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.